Brexucabtagene autoleucel CAR-T therapy is highly efficacious in overcoming resistance to Bruton’s tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma. However, many patients relapse post CAR-T therapy with dismal outcomes. To dissect the underlying mechanisms of sequential resistance to BTKi and CAR-T therapy, we performed single-cell RNA sequencing analysis for 66 samples from 25 patients treated with BTKi and/or CAR-T therapy and conducted in-depth bioinformatics analysis. Our analysis revealed that HSP90-MYC-CDK9 network is the primary driving force of therapeutic resistance. For more details, please check our [manuscript](to be added).
To reproduce the analysis and figures presented in our manuscript please see the Reproducibility folder.
Check out our raw datasets at the European Genome-Phenome Archive (EGA) database under the accession code EGAS00001005019.
Please cite our [manuscript](to be added).